Ken Cunningham, Chairman of Abzena Limited, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO) following completion of the Acquisition by Welsh, Carson, Anderson & Stowe (WCAS)
Dr. Goldman will focus his efforts on the growth of Abzena as the leading provider of outsourced and integrated services in the biologics early development space by establishing new partnerships with clients, building internal manufacturing capacity and pursuing strategic acquisitions. He joins the company after achieving significant success as the CEO of Aptuit LLC, a […] Read more
Abzena announces a research and licence agreement with Tmunity Therapeutics, a T cell engineering company
Cambridge, UK, 19 September 2018 – Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen […] Read more
Faron Pharmaceuticals Ltd announces that it has filed a Clinical Trial Application (CTA)
Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody™ platform. Faron will develop Clevegen®, a novel anti-Clever-1 antibody, for the treatment of selected metastatic or inoperable tumours. It’s great to see an ABZENA Inside product […] Read more
Update on partial monetisation of ABZENA Inside portfolio
Cambridge, UK, 16 August 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Company’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, confirms that following the announcement today of a recommended cash offer for the Company, it has terminated discussions to sell an interest in its entitlements […] Read more
Recommended Cash Offer for Abzena plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET […] Read more
Release of first GMP drug substance for an ABZENA Inside product manufactured by Abzena
Cambridge, UK, 8 August 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody platform™. The product is a novel therapeutic […] Read more
Abzena signs protein engineering agreement with NYU Langone Health
Cambridge, UK, 30 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering and drug […] Read more
Abzena and Telix sign strategic manufacturing and bioconjugation agreement
Cambridge, UK and Melbourne, Australia, 2 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed GMP manufacturing and bioconjugation agreements with Telix Pharmaceuticals Limited (‘Telix’). The agreements have a combined value of $5.9 million and these projects are […] Read more
Funding update: Seeking to monetise royalty-bearing ABZENA Inside products
Cambridge, UK, 14 June 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Company’, and together with its subsidiaries, the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, provides an update on its fundraising activities. At the time of the recent full-year results announcement on 4 […] Read more
Full year results: a year of transition – revenue growth driven by investment programme
Cambridge, UK, 4 June 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2018. Corporate summary FY18 was a year of transition; ambitious growth targets set […] Read more